Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Where are we with haemolytic uremic syndrome?
Journal Information
Vol. 151. Issue 8.
Pages 329-335 (October 2018)
Download PDF
More article options
Vol. 151. Issue 8.
Pages 329-335 (October 2018)
Where are we with haemolytic uremic syndrome?
Síndrome hemolítico urémico: estado actual
Teresa Caveroa,
Corresponding author

Corresponding author.
, Marina Alonsob
a Servicio de Nefrología, Hospital 12 de Octubre, Madrid, Spain
b Servicio de Anatomía Patológica, Hospital 12 de Octubre, Madrid, Spain
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (3)
Table 1. Extrarenal involvement in atypical haemolytic uraemic syndrome.
Table 2. Complementary tests for the study of thrombotic microangiopathies.
Table 3. Immunological and genetic study of proteins in the alternative complement pathway.
Show moreShow less

Haemolytic uraemic syndrome (HUS) is characterized by microangiopathic haemolytic anaemia with acute kidney injury. It is currently classified into two main categories: Shiga-toxin producing E. coli-haemolytic uraemic syndrome (STEC-HUS) and atypical haemolytic uraemic syndrome (aHUS). Endothelial cell damage is the common pathway in HUS to developing thrombotic microangiopathy. Atypical HUS includes primary, secondary and aHUS due to metabolic diseases. In the majority of aHUS cases, hyperactivity of the alternative complement pathway plays a central role. Therefore, treatment is based on complement inhibitors like eculizumab, a drug that has revolutionized the natural history of the disease. Relapses are frequent after kidney transplant and thus confer a poor prognosis.

Haemolytic uraemic syndrome
Alternative complement pathway
Microangiopathic haemolytic anaemia

El síndrome hemolítico urémico (SHU) se caracteriza por una anemia hemolítica microangiopática con deterioro de función renal. Actualmente se clasifica en SHU asociado a toxina Shiga y SHU atípico, y el mecanismo común consiste en un daño grave del endotelio vascular que origina una microangiopatía trombótica. Dentro del SHU atípico se engloban formas primarias, secundarias y debidas a enfermedades metabólicas. En la gran mayoría de casos de SHU atípico, la hiperactividad de la vía alternativa del complemento juega un papel patogénico central. El tratamiento se basa en el bloqueo de la formación del complejo de ataque de membrana, molécula final de la vía alternativa del complemento, con eculizumab, que ha revolucionado la historia natural de la enfermedad. La recidiva de la enfermedad en el trasplante es frecuente y con muy mal pronóstico para la supervivencia renal.

Palabras clave:
Síndrome hemolítico urémico
Vía alternativa del complemento
Anemia hemolítica microangiopática


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más